Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; pp. viii412 - viii413
Main Authors Drescher, C., Moore, K.N., Liu, J.F., O’Malley, D.M., Wang, E.W., Wang, J.S.-Z., Subbiah, V., Wilky, B.A., Yuan, G., Dupont, C.D., Gonzalez, A.M., Savitsky, D., Coulter, S., Shebanova, O., Dow, E., Ortuzar, W., Buell, J.S., Stein, R.B., Youssoufian, H.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2018
Online AccessGet full text
ISSN0923-7534
1569-8041
1569-8041
DOI10.1093/annonc/mdy288.031

Cover

More Information
ISSN:0923-7534
1569-8041
1569-8041
DOI:10.1093/annonc/mdy288.031